184 related articles for article (PubMed ID: 27810161)
1. Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS network.
Martinez G; Walschaerts M; Le Mitouard M; Borye R; Thomas C; Auger J; Berthaut I; Brugnon F; Daudin M; Moinard N; Ravel C; Saias J; Szerman E; Rives N; Hennebicq S; Bujan L
Fertil Steril; 2017 Feb; 107(2):341-350.e5. PubMed ID: 27810161
[TBL] [Abstract][Full Text] [Related]
2. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
Bujan L; Walschaerts M; Brugnon F; Daudin M; Berthaut I; Auger J; Saias J; Szerman E; Moinard N; Rives N; Hennebicq S
Fertil Steril; 2014 Sep; 102(3):667-674.e3. PubMed ID: 25044088
[TBL] [Abstract][Full Text] [Related]
3. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
4. Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d'Étude et de Conservation des Oeufs et du Sperme network.
Rives N; Walschaerts M; Setif V; Hennebicq S; Saias J; Brugnon F; Auger J; Berthaut I; Szerman E; Daudin M; Bujan L
Fertil Steril; 2017 Mar; 107(3):580-588.e1. PubMed ID: 28069184
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network.
Bujan L; Walschaerts M; Moinard N; Hennebicq S; Saias J; Brugnon F; Auger J; Berthaut I; Szerman E; Daudin M; Rives N
Fertil Steril; 2013 Sep; 100(3):673-80. PubMed ID: 23755953
[TBL] [Abstract][Full Text] [Related]
6. Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma.
Frias S; Van Hummelen P; Meistrich ML; Wyrobek AJ
PLoS One; 2020; 15(12):e0242218. PubMed ID: 33370316
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
8. [Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993].
Naccache P; Decaudin D; Koscielny S; Bendahmane B; Auger J; Munck JN
Bull Cancer; 1996 Apr; 83(4):307-14. PubMed ID: 8680082
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
10. Severe sperm DNA fragmentation may persist for up to 3 years after cytotoxic therapy in patients affected by Hodgkin lymphoma and non-Hodgkin lymphoma.
Farnetani G; Vannucci M; Fino MG; Cioppi F; Rosta V; Palma M; Tamburrino L; Vinci S; Casamonti E; Degl'Innocenti S; Spinelli M; Abrardo C; Marchiani S; Lotti F; Muratori M; Riera-Escamilla A; Krausz C
Hum Reprod; 2024 Mar; 39(3):496-503. PubMed ID: 38177083
[TBL] [Abstract][Full Text] [Related]
11. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
12. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Kamieńska E
Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
[TBL] [Abstract][Full Text] [Related]
13. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
[TBL] [Abstract][Full Text] [Related]
15. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
16. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
17. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM
Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817
[TBL] [Abstract][Full Text] [Related]
18. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the gonadotropin-releasinghormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men.
Krause W; Pflüger KH
Andrologia; 1989; 21(3):265-70. PubMed ID: 2476046
[TBL] [Abstract][Full Text] [Related]
20. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
van den Berg H; Furstner F; van den Bos C; Behrendt H
Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
